Information Provided By:
Fly News Breaks for February 10, 2016
CTIC, INCY
Feb 10, 2016 | 08:20 EDT
Leerink analyst Michael Schmidt views the FDA's full clinical hold on CTI BioPharma's (CTIC) pacritinib as an incremental positive for Incyte (INCY). The analyst points out, however, that he didn't view pacritinib as a significant threat to Incyte's Jakafi franchise in myelofibrosis. Nonetheless, the clinical hold on a potential competitor should remove a small overhang on Incyte shares, Schmidt tells investors in a research note. He reiterates an Outperform rating on the name.
News For INCY;CTIC From the Last 2 Days
There are no results for your query INCY;CTIC